dalteparin has been researched along with Cardiomyopathies in 2 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Park, JL | 1 |
Tanhehco, EJ | 1 |
Kilgore, KS | 1 |
Gralinski, MR | 1 |
Lucchesi, BR | 1 |
Strobel, J | 1 |
Schröder, S | 1 |
2 other studies available for dalteparin and Cardiomyopathies
Article | Year |
---|---|
Reviparin-sodium prevents complement-mediated myocardial injury in the isolated rabbit heart.
Topics: Animals; Anticoagulants; Cardiomyopathies; Complement Activation; Complement C3 Convertase, Alternat | 1997 |
[Postpartum cardiomyopathy].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Anticoagula | 2011 |